CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Other EventsItem 8.01 Other Events.
On February 8, 2018, Celgene Corporation, a Delaware corporation (the “Company”), issued a press release announcing the commencement of its public offering of senior unsecured notes. A copy of the press release is attached hereto as Exhibit 99.1.
Item 8.01 Financial Statements and Exhibits
CELGENE CORP /DE/ ExhibitEX-99.1 2 tv485082_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CELGENE ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES SUMMIT,…To view the full exhibit click here
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
